Description
APG-115 is an investigational medication currently being studied in clinical trials, including for certain types of colorectal cancer. It is being evaluated in combination with another investigational drug called toripalimab. The trials are in early phases (Phase 1), meaning researchers are primarily looking at safety and determining the right dose. These trials are specifically looking at patients whose tumors have certain characteristics, such as MET mutations or TP53 amplification. The goal is to see if this combination is safe and potentially effective for these patients. It is important to remember that APG-115 is not yet approved for treating colorectal cancer or any other condition.
Mechanism of Action
APG-115 is being investigated as a potential cancer treatment. The specific way it works (its molecular target or mechanism of action) is still being studied. Clinical trials are evaluating its effects when given with toripalimab, which is a type of immunotherapy that targets the PD-1 protein on immune cells to help them fight cancer. The combination aims to enhance the body's immune response against the tumor.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.